Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences (RNA) Equity Average (2020 - 2025)

Historic Equity Average for Avidity Biosciences (RNA) over the last 6 years, with Q3 2025 value amounting to $1.5 billion.

  • Avidity Biosciences' Equity Average rose 1301.24% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 1301.24%. This contributed to the annual value of $962.9 million for FY2024, which is 7849.96% up from last year.
  • As of Q3 2025, Avidity Biosciences' Equity Average stood at $1.5 billion, which was up 1301.24% from $1.3 billion recorded in Q2 2025.
  • Avidity Biosciences' 5-year Equity Average high stood at $1.5 billion for Q3 2025, and its period low was $275.3 million during Q2 2021.
  • In the last 5 years, Avidity Biosciences' Equity Average had a median value of $538.3 million in 2023 and averaged $724.5 million.
  • Its Equity Average has fluctuated over the past 5 years, first skyrocketed by 136.78% in 2021, then soared by 18759.05% in 2024.
  • Over the past 5 years, Avidity Biosciences' Equity Average (Quarter) stood at $388.2 million in 2021, then increased by 23.03% to $477.5 million in 2022, then increased by 6.61% to $509.1 million in 2023, then skyrocketed by 187.59% to $1.5 billion in 2024, then rose by 5.14% to $1.5 billion in 2025.
  • Its Equity Average was $1.5 billion in Q3 2025, compared to $1.3 billion in Q2 2025 and $1.4 billion in Q1 2025.